Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 2/20 | 0.54 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.54 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.52 |
| ▸ | BCL2 | P10415 | 1/20 | 0.51 |
| ▸ | GPR88 | Q9GZN0 | 6/20 | 0.49 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | ACACB | O00763 | 1/20 | 0.48 |
| ▸ | PPARA | Q07869 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5350616 | 1.00 | PRKCA (0.54) | PRKCAPRKCDPTPN1BCL2GPR88 | |
| SCHEMBL13802917 | 0.89 | FFAR1 (0.53) | PRKCAPRKCDPTPN1BCL2LTA4H | |
| SCHEMBL5205611 | 0.89 | FFAR1 (0.53) | PRKCAPRKCDPTPN1BCL2LTA4H | |
| SCHEMBL27983817 | 0.88 | KMT2A (0.51) | PTPN1ACACBPPARASMN1; SMN2 | |
| SCHEMBL12195404 | 0.85 | PRKCA (0.54) | PRKCAPRKCDGPR88ACACB | |
| SCHEMBL3349953 | 0.85 | RIPK1 (0.60) | GPR88PPARA | |
| SCHEMBL2481921 | 0.85 | RIPK1 (0.60) | GPR88PPARA | |
| SCHEMBL127326 | 0.85 | RIPK1 (0.60) | GPR88PPARA | |
| SCHEMBL191550 | 0.84 | ATM (0.55) | PRKCAPRKCDPTPN1BCL2LTA4H | |
| SCHEMBL191549 | 0.84 | ATM (0.55) | PRKCAPRKCDPTPN1BCL2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018138739-A1 | NOVEL ANTIESTROGENIC HETEROCYCLIC COMPOUNDS | SUN PHARMA ADVANCED RESEARCH COMPANY LIMITED (IN) | 2018-08-02 | — | — | WO | disclosed |
| US-8497271-B2 | Modulators of G protein-coupled receptor 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2013-07-30 | — | — | US | disclosed |
| EP-2486030-B1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL MYERS SQUIBB CO (US) | 2013-07-24 | — | — | EP | disclosed |
| EP-2486030-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | Bristol-Myers Squibb Company (US) | 2012-08-15 | — | — | EP | disclosed |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | Bristol-Myers Squibb Company and Lexicon Pharmaceuticals, Inc. | 2011-10-06 | — | — | US | disclosed |
| WO-2011044195-A1 | MODULATORS OF G PROTEIN-COUPLED RECEPTOR 88 | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-04-14 | — | — | WO | disclosed |
| US-7196081-B2 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20050192449-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2005-09-01 | — | — | US | disclosed |
| US-6737417-B2 | AN ANTIESTROGENIC AGENT CONTAININING AROMATIC OR HETEROAROMATIC COMPOUNDS CONTAINING HYDROXYCARBONYL OR METAL SALT- HALOGENOALKYL SIDE CHAIN; USEFUL FOR TREATING BREAST CANCER | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2004-05-18 | — | — | US | disclosed |
| EP-1361205-A1 | Compounds with hydroxycarbonyl-halogenalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-11-12 | — | — | EP | disclosed |
| US-20030130347-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-07-10 | — | — | US | disclosed |
| US-20030114524-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chain | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2003-06-19 | — | — | US | disclosed |
| EP-1241158-A1 | COMPOUND HAVING HYDROXYCARBONYL-HALOGENOALKYL SIDE CHAIN | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2002-09-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050192449-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | CYP19A1, HSD17B11, SHBG | PRKCA 4240/4885PRKCD 3586/4885PTPN1 3900/4885 |
| US-20110245264-A1 | Modulators of G Protein-Coupled Receptor 88 | GPR88, GPR68, GRK2 | PRKCA 425/4885PRKCD 500/4885PTPN1 1900/4885 |
| US-20030114524-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chain | HSD17B11, CYP19A1, SHBG | PRKCA 3383/4885PRKCD 2624/4885PTPN1 3429/4885 |
| US-20030130347-A1 | Compounds with hydroxycarbonyl-halogenoalkyl side chains | HSD17B11, CYP19A1, SHBG | PRKCA 3444/4885PRKCD 2649/4885PTPN1 3437/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.